Stocks
Pacira BioSciences, Inc.

Pacira BioSciences, Inc.PCRX

NASDAQHealthcareBiotechnology$25.36-1.15%

Price as of · delayed, not real-time

Specializing in non-opioid pain management and regenerative health solutions, this biopharmaceutical company is known for its flagship EXPAREL product, a long-acting local analgesic. Investors monitor its pipeline for novel therapies addressing postsurgical pain and nerve block applications. The firm competes in the growing market for opioid alternatives amid increased regulatory scrutiny of addiction risks.

Market Cap: $1.0B52W Range: $18.80-$27.66

Congressional Interest in Pacira BioSciences, Inc. (PCRX)

3 members of Congress have disclosed 17 trades in Pacira BioSciences, Inc. (PCRX), a Healthcare company. The buy/sell breakdown shows 17 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.

Total Disclosures
17
Unique Politicians
3
Buys
17
Sells
0

Who in Congress Is Trading PCRX?

2022-06-03$15-$50
Stock
2021-05-06$1K-$15K
Stock
2021-04-20$1K-$15K
Stock
2021-01-25$1K-$15K
Stock
2021-01-15$1K-$15K
Stock
2020-11-02$1K-$15K
Stock
2020-02-11$1K-$15K
Stock
2019-09-26$15K-$50K
Stock
2019-08-23$1K-$15K
Stock
2019-05-31$15K-$50K
Stock
2019-05-31$15K-$50K
Stock
2019-05-30$15K-$50K
Stock
2017-01-13$15K-$50K
Stock
2016-12-13$15K-$50K
Stock
2016-04-11$1K-$15K
Stock
2015-12-09$15K-$50K
Stock
2015-04-17$15K-$50K
Stock